Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.5052W HIGH $11.30
Volume
520.41 K
Value Traded
6.41 M
Short % Float
10.15%
+8.39%Week
-40.64%1 Month
-69.06%3 Month
-76.52%6 Month
-76.72%5 Year
-76.72%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
44.76 M
EPS (TTM)
-1.95
P/E Ratio
-
Ent. Value
38.74 M
Total Shares
26.62 M
Float Shares
16.20 M
Insiders
39.19%
Institutions
31.27%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CVRX Catalyst Timeline
Dated clinical, regulatory and corporate events for CVRx, Inc.
Past FDA Catalysts and PDUFA Decisions
How CVRX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
CVRx, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every CVRX program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Binkowski BrentOfficer (CHIEF OPERATING OFFICER) | Buy | 26,223 56,514 held | $2.91 | 08/13/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CVRX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| NEA Management Company, LLC | 0.6 % (-45.5 %) | 10.04 M | 1.95 M | -3.54% ( -71.64 K) |
CVRX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CVRX ranks across every disease it competes in
Competitive Position is a premium feature
See how CVRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCVRX News
CVRX▲ +7%on this news
CVRx Responds to Letter from Pointillist Family Office
CVRx, Inc. has responded to a letter from Jorey Chernett of Pointillist Family Office, emphasizing its commitment to shareholder interests and the value of its Barostim therapy. The Board acknowledges that the current valuation does not reflect the business's potential and remains open to constructive engagement with shareholders. Barostim is the only FDA-approved neuromodulation therapy for heart failure.
Read more →CVRX▲ +10.9%on this newsshared move
CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy
CVRx, Inc. announced that Devoted Health has issued a Medicare Advantage coverage policy for Barostim therapy, effective July 17, 2026. This policy will cover patients meeting FDA-approved indications and those enrolled in the BENEFIT-HF trial. This development is part of a series of positive reimbursement updates for Barostim in 2026, enhancing access for heart failure patients.
Read more →CVRX▼ -59.8%on this news
CVRx Reports Second Quarter 2026 Financial and Operating Results
CVRx reported a 16% increase in total revenue for Q2 2026, reaching $15.7 million. The company saw significant growth in U.S. revenue and active implanting centers. However, the outlook for the remainder of the year has been downgraded due to fewer sales territories and lower productivity. The recent Medicare Advantage coverage policy from Humana for Barostim therapy is a positive development.
Read more →CVRXCVRx to Present at Canaccord Genuity's 46th Annual Growth Conference
CVRx, Inc. will present at Canaccord Genuity's 46th Annual Growth Conference on August 11, 2026. The presentation will highlight the company's innovative neuromodulation solutions for cardiovascular diseases, particularly their FDA-approved device, Barostim. A live webcast will be available, along with an archived version post-event.
Read more →CVRXCVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026
CVRx, Inc. plans to release its second quarter 2026 financial results on August 6, 2026, after market close. A conference call will follow at 4:30 p.m. Eastern Time to discuss these results. The company specializes in neuromodulation solutions for cardiovascular diseases, with its Barostim device being FDA-approved for heart failure treatment.
Read more →CVRXCVRx Announces Chief Financial Officer Transition
CVRx announced that Jared Oasheim, their Chief Financial Officer, will be stepping down to pursue other opportunities. Mr. Oasheim will remain with the company until a successor is appointed and will act as an advisor through February 2027. He has been with CVRx since 2015, contributing significantly to its financial structure and successful IPO. The company is currently searching for a new CFO and continues to focus on its innovative neuromodulation solutions for cardiovascular patients.
Read more →CVRXCVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
CVRx, Inc. will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The presentation will highlight their innovative neuromodulation solutions for cardiovascular diseases, particularly the Barostim device, which is FDA-approved for heart failure. A live webcast will be available for interested parties.
Read more →CVRXCVRx to Present at the William Blair 46th Annual Growth Stock Conference
CVRx, Inc. will present at the William Blair 46th Annual Growth Stock Conference on June 2, 2026. The presentation will highlight the company's innovative neuromodulation solutions for cardiovascular diseases, particularly focusing on their FDA-approved device, Barostim. A live webcast will be available, with an archived version accessible later.
Read more →CVRX▲ +10%on this news
CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy
CVRx has announced that Humana will provide Medicare Advantage coverage for Barostim therapy starting May 1, 2026. This policy is significant as it marks the first coverage for Barostim, aimed at improving access for heart failure patients. The announcement follows other positive reimbursement developments and reflects ongoing efforts to educate payers about the therapy's benefits.
Read more →CVRXCVRx Reports First Quarter 2026 Financial and Operating Results
CVRx, Inc. reported a strong financial performance for Q1 2026, with total revenue reaching $14.8 million, a 20% increase from the previous year. U.S. revenue also saw a notable rise of 22%, driven by growth in the heart failure business. The company activated its first site and enrolled its first patient in the BENEFIT-HF clinical trial, aiming to expand the Barostim indication significantly.
Read more →CVRXCVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population
CVRx has announced the enrollment of the first patient in the BENEFIT-HF trial, which aims to evaluate the Barostim therapy in a significantly expanded heart failure population. The trial is expected to enroll 2,500 patients across 150 centers in the U.S. and Germany. If successful, it could potentially triple the patient population eligible for Barostim therapy, enhancing access for those suffering from heart failure.
Read more →CVRXCVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026
CVRx, Inc. will announce its first quarter 2026 financial results on May 11, 2026. A conference call will follow at 4:30 p.m. ET to discuss these results. The company specializes in neuromodulation solutions for cardiovascular diseases, with its Barostim device being FDA-approved for heart failure treatment.
Read more →CVRXCVRx Announces Nomination of Michael Dale for Election to the Board of Directors
CVRx, Inc. has nominated Michael Dale for election to its Board of Directors at the upcoming annual meeting on June 1, 2026. Dale, who is currently the CEO of Axogen, Inc., has a strong background in the medical device sector, which CVRx believes will enhance its strategic direction, particularly in promoting its Barostim therapy for heart failure.
Read more →CVRX▲ +9.2%on this news
CVRx Reports Preliminary First Quarter 2026 Financial Results
CVRx reported preliminary financial results for Q1 2026, projecting revenues of $14.7 to $14.8 million, marking a 20% increase from the previous year. The company noted improved Medicare Advantage prior authorization rates and activated the first site for the BENEFIT-HF clinical trial. Despite increased operating expenses, the gross margin is expected to reach 87%.
Read more →CVRXCVRx, Inc. Investigated by the Portnoy Law Firm
CVRx, Inc. is under investigation by the Portnoy Law Firm for possible securities fraud, with a potential class action being considered for investors. The investigation follows a significant decline in CVRx's stock price, which plummeted 46.3% after the company reported disappointing first quarter revenues. Subsequent announcements regarding lower full-year revenue guidance and challenges in the integration of new sales personnel have further impacted investor confidence. This situation has led to a steep decline in share value, prompting legal scrutiny.
Read more →CVRXCVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting
CVRx, Inc. announced the schedule for scientific presentations at the THT 2026 meeting, focusing on Barostim therapy outcomes. The presentations will include late-breaking data from the REBALANCE Registry, showcasing the therapy's safety and benefits in over 400 patients. The conference will feature various sessions on cardiac energetics and hospitalization impacts related to Barostim.
Read more →CVRX▼ -6.4%on this news· ran to -20% by day 3
CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
CVRx, Inc., a medical device company, reported its financial results for Q4 and full year 2025, showcasing a revenue increase to $56.7 million, up 10% year-over-year. The U.S. revenue also grew by 10%, aided by an increase in active implanting centers. CVRx announced the initiation of the BENEFIT-HF trial, expected to enhance market access. However, the company continues to face significant net losses, amounting to $53.3 million for the year.
Read more →About CVRx, Inc.
Headquarters9201 WEST BROADWAY AVENUE, MINNEAPOLIS, MN, 55445
BIOPHARMAWATCH ELITE PLUS
Trade the next CVRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime